Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Wonderland Capital

Founders Peixing Jiang

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 14
Average round size
info
The average size of a deal this fund participated in
$10M
Portfolio companies 14
Rounds per year 2.00
Lead investments 2
Key employees 1
Stages of investment
Early Stage Venture

Areas of investment

  • Medical
  • Biotechnology
  • Electronics
  • Industrial
  • Manufacturing
Summary

In 2017 was created Wonderland Capital, which is appeared as VC. The company was established in Asia in China. The main office of represented VC is situated in the Beijing.

The current fund was established by Peixing Jiang. Besides them, we counted 1 critical employee of this fund in our database.

The important activity for fund was in 2017. The common things for fund are deals in the range of 5 - 10 millions dollars. The average startup value when the investment from Wonderland Capital is 50-100 millions dollars. The fund is generally included in less than 2 deals every year.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Magpie Pharmaceuticals, Ruibosi Medical Technology (Ribose) Among the most successful fund investment fields, there are Biotechnology, Health Care.

The standard case for the fund is to invest in rounds with 2-3 partakers. The meaningful sponsors for the fund in investment in the same round are Red Star Macalline, National SME Development Fund, Beijing Prudential Capital Management. In the next rounds fund is usually obtained by Sangel Capital.

Read more

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Adani Capital Central, Central Region, Singapore
Beecken Petty O'Keefe & Company Chicago, Illinois, United States
Black Horse Investments Düsseldorf, Germany, Nordrhein-Westfalen
Chaosheng Capital -
CN-Healthcare Beijing, China, Haidian
Cobin Angels Mazowieckie, Poland, Warsaw
Comcast Interactive Media Pennsylvania, Philadelphia, United States
Daxin Chuangtou China, Guangdong Province, Panyu District
ETFS Capital England, London, United Kingdom
First Rays Venture Partners California, San Francisco, United States
Gaydoul Group Pfaffikon, Switzerland, Zurich
IdeaLab Capital Partners California, Pasadena, United States
Liberty Media Colorado, Englewood, United States
ShangHai MOO Metal Detector Co., Ltd China, Shanghai
Synergy Marketing Japan, Osaka, Osaka Prefecture
ThedaCare Appleton, United States, Wisconsin
Thieme Baden-Wurttemberg, Germany, Stuttgart
Venture Farmers -
VvAA Netherlands, Utrecht, Utrecht
Xoogler -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Lianxin Digital

$15M24 May 2024 Quzhou, Zhejiang, China

Zhishu Technology

Electrical Distribution
Electronics
Medical Device
08 Feb 2023 Daxing, Beijing, China

UGa Technology

Electrical Distribution
Electronics
Semiconductor
01 Feb 2023 Haidian, Beijing, China

QBEAM

3D Printing
Hardware
Medical
$15M23 Dec 2022 Beijing, Beijing, China

VACURE Biotechnology

Biotechnology
Health Diagnostics
Manufacturing
Medical
Medical Device
$1M22 Dec 2021 Chengdu, Sichuan, China

Slichem

Advanced Materials
Electronics
Industrial
Manufacturing
$105M21 May 2021 Shijiazhuang, Hebei, China

Ruibosi Medical Technology (Ribose)

Health Care
Medical
$7M19 Apr 2019 Gulou District, China

Magpie Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
01 Sep 2017 Yuexiu District, Guangdong Province

Matrix Optoelectronics

01 Jan 2014 Suzhou, Jiangsu, China

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Wonderland Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 14
Average round size 10M
Rounds per year 2.00
Peak activity year 2018
Lead investments 2
Group Appearance index 0.57

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Lianxin Digital

$15M24 May 2024 Quzhou, Zhejiang, China

Zhishu Technology

Electrical Distribution
Electronics
Medical Device
08 Feb 2023 Daxing, Beijing, China

UGa Technology

Electrical Distribution
Electronics
Semiconductor
01 Feb 2023 Haidian, Beijing, China

QBEAM

3D Printing
Hardware
Medical
$15M23 Dec 2022 Beijing, Beijing, China

VACURE Biotechnology

Biotechnology
Health Diagnostics
Manufacturing
Medical
Medical Device
$1M22 Dec 2021 Chengdu, Sichuan, China

Slichem

Advanced Materials
Electronics
Industrial
Manufacturing
$105M21 May 2021 Shijiazhuang, Hebei, China

Ruibosi Medical Technology (Ribose)

Health Care
Medical
$7M19 Apr 2019 Gulou District, China

Magpie Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
01 Sep 2017 Yuexiu District, Guangdong Province

Matrix Optoelectronics

01 Jan 2014 Suzhou, Jiangsu, China
Crunchbase icon

Content report

The following text will be sent to our editors: